Nasdaq

Aflibercept 8 mg and EYLEA® (aflibercept) Injection Presentations at ARVO Provide New Insights into the Treatment of Serious Retinal Diseases

TARRYTOWN, N.Y., April 17, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and its collaborator Bayer today announced that aflibercept 8 mg and EYLEA® (aflibercept) Injection ...
Monthly Prescribing Reference

Intraocular Inflammation More Common With Aflibercept Injections in Real-World Setting

The analysis included 41 patients who were treated with 136 intravitreal aflibercept, 8mg, injections. HealthDay News — The incidence of mild intraocular inflammation (IOI) in the real world occurs ...
Nasdaq

EYLEA HD® (aflibercept) Injection 8 mg Data at EURETINA Reinforce Long-term Durability, Sustained Fluid Control and Safety Profile

TARRYTOWN, N.Y., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new analyses of EYLEA HD® (aflibercept) Injection 8 mg and EYLEA® (aflibercept) ...
The American Journal of Managed Care

High-Dose, Extended Duration Aflibercept Injections Benefit Patients With DME, nAMD

Results from the pivotal PHOTON and PULSAR trials highlighted the success of 8-mg aflibercept every 12 or 16 weeks in patients with diabetic macular edema (DME) and neovascular age-related macular ...
Healio

Number of initial aflibercept injections may affect visual outcomes in DME

Please provide your email address to receive an email when new articles are posted on . SEATTLE — The number of initial monthly aflibercept injections may play a role in achieving optimal visual ...
FiercePharma

EYLEA® (aflibercept) Injection Recommended for Approval for the Treatment of Visual Impairment due to Diabetic Macular Edema in the European Union

EYLEA® (aflibercept) Injection Recommended for Approval for the Treatment of Visual Impairment due to Diabetic Macular Edema in the European Union TARRYTOWN, N.Y., June 27, 2014 /PRNewswire/ -- ...
Seeking Alpha

EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases

TARRYTOWN, N.Y., April 29, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) today announced the presentation of positive long-term results and subgroup analyses from the pivotal ...
FiercePharma

EYLEA® (aflibercept) Injection Demonstrates Significantly Greater Gains in Visual Acuity than Both Bevacizumab and Ranibizumab in NIH-Sponsored Diabetic Macular Edema Study

EYLEA® (aflibercept) Injection Demonstrates Significantly Greater Gains in Visual Acuity than Both Bevacizumab and Ranibizumab in NIH-Sponsored Diabetic Macular Edema Study TARRYTOWN, N.Y., Oct. 17, ...
Healio

At 1 year, aflibercept injections did not impact CNV conversion rates

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. FORT LAUDERDALE, Fla. — Patients with intermediate ...
Seeking Alpha

EYLEA HD® (aflibercept) Injection 8 mg Positive Phase 3 Results in Patients with Macular Edema following Retinal Vein Occlusion Presented at Angiogenesis Meeting

TARRYTOWN, N.Y., Feb. 08, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) today announced the first presentation of positive results from the Phase 3 QUASAR trial investigating EYLEA ...